- Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
- Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
- Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
- Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
- Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
- Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
- Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
More ▼
Key statistics
On Friday, Centessa Pharmaceuticals PLC (CNTA:NSQ) closed at 10.57, -15.10% below its 52-week high of 12.45, set on Mar 22, 2024.
52-week range
Open | 10.37 |
---|---|
High | 10.66 |
Low | 10.26 |
Bid | 4.25 |
Offer | 11.04 |
Previous close | 10.53 |
Average volume | 124.37k |
---|---|
Shares outstanding | 100.31m |
Free float | 88.67m |
P/E (TTM) | -- |
Market cap | 1.06bn USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼